F/M Investments’s Ligand Pharmaceuticals LGND Stock Holding History

F/M Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$584K	Sell	1,853 -148	-7%	-$34.9K	0.03%	244
2026 Q1	$399K	Sell	2,001 -44,129	-96%	-$8.73M	0.03%	255
2025 Q4	$8.72M	Sell	46,130 -5,346	-10%	-$1.03M	0.33%	70
2025 Q3	$9.12M	Sell	51,476 -1,031	-2%	-$153K	0.35%	67
2025 Q2	$5.97M	Buy	52,507 +262	+0.5%	+$28K	0.22%	95
2025 Q1	$5.49M	Sell	52,245 -638	-1%	-$72.1K	0.22%	90
2024 Q4	$5.67M	Sell	52,883 -81,416	-61%	-$9.2M	0.21%	102
2024 Q3	$13.4M	Sell	134,299 -411	-0.3%	-$41.4K	0.42%	62
2024 Q2	$11.4M	Buy	+134,710	New	+$10.7M	0.41%	68

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

F/M Investments's LGND Position: Q2 2026 in Review

F/M Investments reduced its Ligand Pharmaceuticals (LGND) stake by 7.4% in Q2 2026, selling an estimated $34.9K and leaving 1,853 shares worth $584K. The position accounts for 0.03% of the portfolio, ranked #244.

F/M Investments first reported a position in LGND in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.4M in Q3 2024. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

F/M Investments held 1,853 shares of Ligand Pharmaceuticals worth $584K as of Q2 2026.
F/M Investments sold 148 Ligand Pharmaceuticals shares in Q2 2026, an estimated $34.9K.
Ligand Pharmaceuticals made up 0.03% of F/M Investments's portfolio in Q2 2026, its #244 holding.
F/M Investments first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
F/M Investments's Ligand Pharmaceuticals position peaked at $13.4M in Q3 2024.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.